Clinical Trials · NCT00853047

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Name: Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Octreotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Lexicon Pharmaceuticals
Enrollment: 23
Start date: Mar 2009
Locations: 9 sites, United States
Primary endpoint: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase

View Octreotide compound reference